Scientists have made a significant advance in gene therapy that could one day turn off the extra chromosome causing Down syndrome. Researchers at Beth Israel Deaconess Medical Center and Harvard Medical School used a modified CRISPR/Cas9 technique to insert the XIST gene into chromosome 21, achieving 20-40% integration efficiency in human stem cells. This approach targets the entire extra chromosome rather than individual genes.

Down syndrome affects approximately 1 in 640 babies born in the United States, making it the most common chromosomal condition. The team's innovation builds on XIST's natural ability to silence one of two X chromosomes in biological females. By adapting this mechanism for chromosome 21, researchers created a proof-of-concept that could eventually treat not just Down syndrome but other aneuploidies as well.

While the technique didn't silence chromosomes in most cells tested, it represents a valuable breakthrough in targeted chromosome therapy. The modified CRISPR method successfully integrated the 14 kb XIST gene exactly where needed. Future research must confirm safety through animal models and verify that silencing the extra chromosome improves physical and cognitive health without off-target effects.